
CLARIFICATION OF CONTENTS IN ARTICLES PUBLISHED IN THE EDGE NEWSPAPER

The Board of Directors (the “**Board**”) of OUE Lippo Healthcare Limited (“**Company**” and together with its subsidiaries, the “**Group**”) refers to the articles published on 20 November 2017 by The Edge Malaysia titled “Singapore-listed OUE to sell prized KL Land” and The Edge Singapore titled “OUE Lippo Healthcare, former IHC, to sell prized KL land” (collectively, the “**Articles**”).

The Company wishes to highlight and clarify the following:

1. It was reported in the Articles that the Company “is shelving plans to develop a prime parcel of land located in the vicinity of Petronas Twin Towers and Jalan Bukit Bintang in Kuala Lumpur and putting it up for sale.” This suggests that a decision has been made and a process underway to effect the decision.
2. The Company wishes to clarify that it is constantly evaluating potential opportunities so as to enhance value and capital allocation for the Group and its shareholders. As part of such evaluation, the Company may consider options available in relation to the Group’s assets and business including the land referred to in the Articles (the “**Land**”) but any such evaluation is exploratory and preliminary. No decision has been made by the Company to sell the Land (or to shelve any development plans).
3. It was also reported in the Articles that the “vendor may be able to get as much as RM200 million [(approximately \$65.3 million)] – which is more than double what [the Company] paid six years ago – for the 1.17-acre, or 50,860 sq ft, parcel in Jalan Kia Peng”.
4. As stated above, the Company’s evaluation of its options in respect of the Land are exploratory and preliminary. There is no clear basis at this time for stating any expected valuation or expected returns on the sale of the Land (if any).

The Company will make appropriate announcements on SGXNET, in accordance with the requirements of the Catalist listing rules, if and when there are material corporate or business developments to be brought to shareholders’ attention. In the meantime, shareholders are advised to exercise caution in dealing or trading in their shares in the Company.

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

By Order of the Board,
OUE Lippo Healthcare Limited

Dr. Wong Weng Hong
Chief Executive Officer and Executive Director

21 November 2017

*This announcement has been prepared by the Company and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).